Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10145028 | 0.88 | MAPT (0.50) | ADRB2ADRB1ADRB3ALDH1A1CYSLTR1 | |
| SCHEMBL27294341 | 0.86 | ADRB2 (0.62) | ADRB2ADRB1ADRB3ALDH1A1NPC1 | |
| SCHEMBL4872864 | 0.85 | ADRB2 (0.62) | ADRB2ADRB1ADRB3ALDH1A1NPC1 | |
| SCHEMBL6898560 | 0.85 | ALDH1A1 (0.53) | ADRB2ADRB1ADRB3ALDH1A1CYSLTR1 | |
| SCHEMBL8567735 | 0.85 | RAB9A (0.50) | ADRB2ADRB1ADRB3ALDH1A1NPC1 | |
| SCHEMBL6942378 | 0.85 | ADRB2 (0.48) | ADRB2ADRB1ADRB3ALDH1A1CYSLTR1 | |
| SCHEMBL1092605 | 0.84 | MAOB (0.59) | ADRB2ADRB1ADRB3ALDH1A1NPC1 | |
| SCHEMBL20395893 | 0.84 | MAPT (0.44) | ADRB2ADRB1ADRB3ALDH1A1NPC1 | |
| SCHEMBL644117 | 0.84 | MAPT (0.44) | ADRB2ADRB1ADRB3ALDH1A1NPC1 | |
| SCHEMBL31589814 | 0.84 | CYSLTR1 (0.53) | ADRB2ADRB1ADRB3ALDH1A1CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113226377-B | Antibody drug conjugates comprising an eltrinastine derivative | 法马马有限公司 | 2022-10-18 | — | — | CN | disclosed |
| WO-2022204150-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | BLUE OAK PHARMACEUTICALS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| CN-111116419-B | Treprostinil intermediate and preparation process thereof | 江苏豪森药业集团有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-11225452-B2 | Synthesis of intermediates for producing prostacyclin derivatives | UNITED THERAPEUTICS CORPORATION (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200369592-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | UNITED THERAPEUTICS CORPORATION (US) | 2020-11-26 | — | — | US | disclosed |
| US-10774027-B2 | Synthesis of intermediates for producing prostacyclin derivatives | UNITED THERAPEUTICS CORPORATION (US) | 2020-09-15 | — | — | US | disclosed |
| CN-111116419-A | Treprostinil intermediate and preparation process thereof | 江苏豪森药业集团有限公司 | 2020-05-08 | — | — | CN | disclosed |
| US-20190233362-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | UNITED THERAPEUTICS CORPORATION (US) | 2019-08-01 | — | — | US | disclosed |
| US-10196342-B2 | Synthesis of intermediates for producing prostacyclin derivatives | UNITED THERAPEUTICS CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-9771345-B2 | Coferons and methods of making and using them | CORNELL UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-6939866-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | disclosed |
| EP-1326860-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2003047584-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003047585-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BENZOFURANYL SUBSTITUTED 3-CYANOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SOLID TUMOURS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774027-B2 | Synthesis of intermediates for producing prostacyclin derivatives | PTGIS, PTGIR, PTGES | ADRB2 1474/4885ADRB1 2169/4885ADRB3 1287/4885 |
| US-20040044015-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | ADRB2 319/4885ADRB1 574/4885ADRB3 248/4885 |
| US-11225452-B2 | Synthesis of intermediates for producing prostacyclin derivatives | PTGIS, PTGIR, PTGS2 | ADRB2 248/4885ADRB1 895/4885ADRB3 1036/4885 |
| US-20190233362-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | PTGIS, PTGIR, PTGES | ADRB2 1474/4885ADRB1 2169/4885ADRB3 1287/4885 |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | ADRB2 1490/4885ADRB1 2961/4885ADRB3 2673/4885 |
| US-10196342-B2 | Synthesis of intermediates for producing prostacyclin derivatives | PTGIS, PTGIR, PTGES | ADRB2 1474/4885ADRB1 2169/4885ADRB3 1287/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | ADRB2 1490/4885ADRB1 2961/4885ADRB3 2673/4885 |
| US-20200369592-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | PTGIS, PTGIR, PTGES | ADRB2 1474/4885ADRB1 2169/4885ADRB3 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.